Chiasma Inc. (CHMA) Reaches New 12-Month Low at $2.41
Chiasma Inc. (NASDAQ:CHMA) shares reached a new 52-week low during trading on Friday . The stock traded as low as $2.41 and last traded at $2.41, with a volume of 172,955 shares traded. The stock had previously closed at $2.63.
Separately, Cowen and Company reaffirmed a “hold” rating on shares of Chiasma in a research report on Friday, May 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $14.63.
The company has a 50-day moving average of $2.78 and a 200-day moving average of $5.43. The stock’s market cap is $59.67 million.
Chiasma (NASDAQ:CHMA) last issued its earnings results on Wednesday, August 10th. The company reported ($1.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.47. On average, equities research analysts expect that Chiasma Inc. will post ($3.14) EPS for the current year.
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.